中國北京和日本長野，2020年11月30日-北京百奧賽圖基因生物技術有限公司（以下簡稱"百奧賽圖"）今日宣布，已與日本Ina Research Co., Ltd.（以下簡稱"INA"）簽訂商業代理協議，以拓展百奧賽圖在日本市場的業務。
 
 
作為世界上最大的制藥及銷售市場之一，日本在創新藥物研發方面享有盛譽。此次合作將把百奧賽圖創新的動物模型及國際水準的抗體藥物發現評價平臺及能力介紹給日本腫瘤免疫、自身免疫等各疾病領域的基礎研究人員及新藥研發人員。根據協議，INA作為百奧賽圖的銷售代理及分銷商，將負責百奧賽圖動物模型及臨床前藥理藥效服務在日本的推廣。


百奧賽圖創始人、董事長和CEO沈月雷博士表示：“INA和百奧賽圖都致力于助力合作伙伴的新藥研發，雙方在不同的藥物開發階段具有各自的優勢，本次合作通過雙方平臺優勢互補能帶來更大的價值。我們相信通過雙方團隊的緊密合作，能為日本的客戶及合作伙伴們提供一體化、整合性的新藥研發平臺。”
 
INA董事長和CEO Kenshi Nakagawa先生表示：“近年來我們感受到日本市場對于優質動物模型和臨床前動物體內藥效評價服務不斷增長的需求，尤其是在免疫治療領域。百奧賽圖的模型和服務能力已被美國、歐洲和中國的許多客戶和合作伙伴包括多家跨國藥企所認可。我們很高興能夠和百奧賽圖一起將這些先進的模型和高質量的服務介紹給日本企業和機構，加速新藥創新。”
 
 
通過本次合作，百奧賽圖的產品和服務可以被快速推介給INA穩定的客戶群體，包括頂尖藥企、生物技術公司和研究機構。INA在10月初已經承辦了一次在線宣講，根據協議，INA將通過更多線上線下的推廣活動來提升百奧賽圖在日本的知名度。
 
關于百奧賽圖
  
百奧賽圖是一家創新技術驅動新藥研發的國際性生物技術公司，致力于成為全球新藥發源地，以專注技術創新、持續新藥產出、守護人類健康為使命。基于百奧賽圖自主研發并擁有完全獨立知識產權的全人抗體RenMab^®、RenLite^TM、RenNano^TM小鼠，將單細胞抗體發現技術平臺、高效的基因編輯模型開發平臺、規模化動物模型供應平臺、快速的動物體內外藥效評價平臺、強大的臨床開發能力有機整合在一起，形成了獨具特色、涵蓋藥物研發全流程的新藥研發體系。公司成功戰略轉型為Biotech，未來將更聚焦于創新抗體藥物研發。隨著規模化抗體藥物研發-“千鼠萬抗”計劃的實施，百奧賽圖將攜手全球合作伙伴，共同加速新藥研發。百奧賽圖總部位于北京，在江蘇海門、美國波士頓、上海等地設有分支機構，全資子公司祐和醫藥專注于臨床開發。
 
關于INA
    
Ina Research 成立于 1974 年，總部位于日本長野縣的伊納市，在東京設有辦事處。該公司的股票在JASDAQ交易所公開交易。Ina 主要為制藥行業的客戶進行分析和安全性和有效性研究，客戶也包括生產農業化學品和醫療設備的公司。Ina的服務及研究領域包括藥物依賴研究、中樞神經系統療法的療效研究、癌癥研究、生殖和發育毒性研究以及動物模型。Ina與學術機構合作，在園區建立了一個研究中心，用以開展由日本醫學研究開發機構資助的 CAR-T治療的非臨床安全研究。
 
Biocytogen Teams With Ina Research To Boost Presence In Japan
 
Beijing, China and Nagano, Japan; November 30, 2020-Beijing Biocytogen Co., Ltd. (hereinafter “Biocytogen”) announced today that it has entered into a commercial agency agreement with Ina Research Co., Ltd. (hereinafter “INA”) to expand its business in Japan market.
 
As one of the world’s largest pharmaceutical markets, Japan has an established reputation for innovative drug research and development. The partnership will help introduce Biocytogen’s innovative animal models and its world-class antibody drug research capabilities to Japanese customers in various therapeutic fields including but not limited to immuno-oncology and auto-immune diseases. Under the agreement, INA represents Biocytogen as a sales agent and distributor to promote Biocytogen’s animal models and research services and capabilities in Japan.
 
“As both INA and Biocytogen having a strong focus on supporting pharmaceutical partner’s development on novel therapeutics, each has strength at different drug development stages. Therefore, the partnership would be a perfect match and create added value. By working as a team, we can provide a streamlined drug discovery and development platform to our business in Japan.” said Yuelei Shen, Ph.D., president and CEO of Biocytogen.
 
“We feel the thriving demand in Japan for animal models and non-clinical in vivo drug efficacy evaluation services, especially in the field of immunotherapy. Biocytogen‘s animal models and research capabilities have been recognized by  world-wide customers including top MNCs in US, Europe and China for years and we would love to introduce them into Japan to support our customers and more importantly, to help accelerate drug innovation here in Japan.” said Kenshi Nakagawa, president and CEO of INA.
 
The partnership gives Biocytogen immediate access to INA’s well-established Japanese customer network including top pharmas, biotechs and institutes in the country. To fulfill the agreement, INA has already hosted a webinar in early October and will launch more events and campaigns to raise awareness of the models and services provided by its newly forged partner, Biocytogen.
 
Company Profile
 
About Beijing Biocytogen Co., Ltd.
 
Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies. The company is committed to becoming a global headstream of new drugs and bringing the benefits to the patients around the world as its mission. Biocytogen has established a highly integrated antibody drug discovery platform based on a series of genetically-modified animal models. Biocytogen has developed the RenMab^TM mouse model for fully human antibodies production with robust humoral responses, highly diverse antibody repertoire and superior affinity.
 
Biocytogen has launched a pioneering antibody drug development plan (Project Integrum https://biocytogen.com/renmab-mouse/project-integrum/) to tackle difficult targets based on the immunization of RenMab^TM knockout mice. Nearly 1,500 targets knockout mouse strains will be generated within 2 years for antibody discovery. Moreover, with the knockout immunization strategy, antibody hits cross-reacting with different species shall be more likely to be generated for better translational efficacy and toxicity evaluation.
 
With the world-class expertise in genetically-engineered animal development and maintenance with large-scale animal breeding capacity, antibody discovery, and preclinical pharmacology services, the company provides seamless integrated antibody discovery services to the biomedical community for a true one-stop solution from target to IND application and has built its collaboration with more than 2,000 partners worldwide, including over 70% of top 20 MNCs.
 
About Ina Research Co., Ltd.
Founded in 1974, Ina Research’s headquarters is in the city of Ina, located in the Nagano prefecture, and it operates offices in Tokyo. The firm’s shares are traded publicly on the JASDAQ exchange.
Ina’s scientists primarily conduct analysis and safety and efficacy studies for customers in the pharmaceutical industry, though the organization also works with companies that produce agricultural chemicals and medical equipment.
Research specialties including drug dependence studies, efficacy studies for central nervous system therapies, cancer studies, reproductive and developmental toxicity studies, and animal models.
Ina has established a research center on Ina’s campus under the collaboration with academic institute to conduct non-clinical safety studies for CAR-T therapy, funded by the Japan Agency for Medical Research and Development.